이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Alagille 증후군 환자에서 Odevixibat의 장기 안전성 및 유효성 (ASSERT-EXT)

2026년 10월 20일 업데이트: Albireo, an Ipsen Company

Alagille 증후군(ASSERT-EXT) 환자에서 Odevixibat(A4250)의 장기 안전성 및 효능을 평가하기 위한 공개 라벨 연구

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

연구 유형

중재적

등록 (실제)

62

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Groningen, 네덜란드, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht, 네덜란드
        • Wilhelmina Children's Hospital UMCU Utrecht
      • Berlin, 독일, 13353
        • Charité - Universitätsmedizin Berlin
      • Hanover, 독일, 30625
        • Medizinische Hochschul
      • Tübingen, 독일, 72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
      • Kuala Lumpur, 말레이시아, 59100
        • University of Malaya Medical Center
    • California
      • San Diego, California, 미국, 92123
        • Rady Children's Hospital
      • San Francisco, California, 미국, 94158
        • UCSF
    • Georgia
      • Atlanta, Georgia, 미국, 30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, 미국, 64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park, New York, 미국, 11042
        • Northwell Health System
      • New York, New York, 미국, 10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York, New York, 미국, 10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx, New York, 미국, 10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati, Ohio, 미국, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, 미국, 97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas, Texas, 미국, 75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston, Texas, 미국, 77030
        • Texas Children's Hospital
      • San Antonio, Texas, 미국, 78215
        • Texas Liver Institute
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires Saint-Luc Bruxelles
      • Birmingham, 영국
        • Birmingham Women's and Children's NHS Foundation Trust
      • London, 영국, SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
      • Florence, 이탈리아
        • AOU Meyer
      • Padova, 이탈리아, 35128
        • Azienda Ospedale University
      • Rome, 이탈리아, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Istanbul, 터키 (Türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital
      • Warsaw, 폴란드, 04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
      • Bron, 프랑스, 69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille, 프랑스
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris, 프랑스, 75015
        • Hopital Necker Enfants Malades

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.

Odevixibat is a small molecule and selective inhibitor of IBAT.

다른 이름들:
  • A4250

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
병용 약물의 기준치로부터의 변화.
기간: 12주차의 기준선(코호트 2).
12주차의 기준선(코호트 2).
지용성 비타민 수준의 기준선 대비 변화.
기간: 12주차의 기준선(코호트 2).
12주차의 기준선(코호트 2).
Change from baseline in pruritus
기간: Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
기간: Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
기간: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
기간: Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
기간: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).

2차 결과 측정

결과 측정
측정값 설명
기간
혈청 담즙산 수치의 기준선 대비 변화
기간: 72주까지의 기준선(코호트 1).
72주까지의 기준선(코호트 1).
혈청 담즙산 수치의 기준선 대비 변화.
기간: 72주까지의 기준선(코호트 1).
72주까지의 기준선(코호트 1).
신체검사 기준선에서 변화된 참가자 수
기간: 72주까지의 기준선(코호트 1).
72주까지의 기준선(코호트 1).
활력징후가 기준선에서 변화된 참가자 수
기간: 72주까지의 기준선(코호트 1).
72주까지의 기준선(코호트 1).
병용 약물의 기준치로부터의 변화
기간: 72주까지의 기준선(코호트 1).
72주까지의 기준선(코호트 1).
실험실 테스트 결과의 기준선 대비 약동학적(PK) Cmax [기간: 1일차, 4주차, 8주차 및 12주차]
기간: 72주까지의 기준선(코호트 1).
72주까지의 기준선(코호트 1).
연구 약물의 혈장 농도 기준선 대비 변화
기간: 1일차, 4주차, 8주차, 12주차(코호트 1).
1일차, 4주차, 8주차, 12주차(코호트 1).
약력학적 매개변수: 혈청 담즙산 수치의 변화
기간: 12주까지의 기준선(코호트 2).
12주까지의 기준선(코호트 2).
Change from baseline in patient reported and observer reported itching and scratching severity scores
기간: Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
기간: Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
기간: Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
기간: Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
기간: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
기간: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
기간: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
기간: Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 72 (cohort 1).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Ipsen Medical Director, Ipsen

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 9월 3일

기본 완료 (추정된)

2027년 2월 15일

연구 완료 (추정된)

2027년 2월 15일

연구 등록 날짜

최초 제출

2021년 8월 13일

QC 기준을 충족하는 최초 제출

2021년 9월 1일

처음 게시됨 (실제)

2021년 9월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 20일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • A4250-015
  • 2023-509028-17-00 (씨티스)
  • 2021-000996-36 (EudraCT 번호)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD 공유 기간

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD 공유 액세스 기준

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .